Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

News

 

 

Terumo Receives GMP Certification for the Manufacturing and Filling of Biologics in PLAJEX™ Polymer Pre-fillable Syringeshttps://www.terumo-europe.com/en-emea/news/terumo-receives-gmp-certification-for-the-manufacturing-and-filling-of-biologics-in-plajex™-polymer-pre-fillable-syringesTerumo Receives GMP Certification for the Manufacturing and Filling of Biologics in PLAJEX™ Polymer Pre-fillable SyringesTokyo, Japan and Leuven, Belgium30/07/2018 22:00:00<p>​Terumo Announces Receiving European Medicines Agency GMP Certification for the Manufacturing and Filling of Biologics in PLAJEX™ Polymer Pre-fillable Syringes at Yamaguchi Subsidiary’s Plant</p>
Terumo Announces Shipping Delays for Products from Ashitaka Factoryhttps://www.terumo-europe.com/en-emea/news/terumo-announces-shipping-delays-for-products-from-ashitaka-factoryTerumo Announces Shipping Delays for Products from Ashitaka FactoryTokyo, Japan03/07/2018 22:00:00<p>​<span style="font-size:14px;">Terumo Corporation (TSE: 4543) today announced shipping delays for products from its Ashitaka Factory in Shizuoka, Japan. This factory produces certain cardiovascular products. No other Terumo factories are affected by this issue.</span></p>
Terumo Acquires CE Marking for Kanshas Drug Coated Balloon Catheter for Lower Extremitieshttps://www.terumo-europe.com/en-emea/news/terumo-acquires-ce-marking-for-kanshas-drug-coated-balloon-catheter-for-lower-extremitiesTerumo Acquires CE Marking for Kanshas Drug Coated Balloon Catheter for Lower ExtremitiesTokyo, Japan19/06/2018 22:00:00<p>Terumo Corporation (TSE: 4543) today announced that it acquired CE marking for the Kanshas™ drug coated balloon (DCB) catheter used in the treatment of lower extremity peripheral arterial disease. With a September launch in Europe, Terumo is expected to be the first Japanese company to launch DCB sales in Europe, and the European launch will be followed with launches in Latin America and Asia, as well. Terumo aims a 10% share of the European DCB market in the future.</p>
New data demonstrate clinical experience with LifePearl microspheres in over 300 hepatocellular carcinoma patientshttps://www.terumo-europe.com/en-emea/news/new-data-demonstrate-clinical-experience-with-lifepearl-microspheres-in-over-300-hepatocellular-carcinoma-patientsNew data demonstrate clinical experience with LifePearl microspheres in over 300 hepatocellular carcinoma patientsLeuven, Belgium18/06/2018 22:00:00<p>​Key publication with real life clinical experience in over 300 patients with Hepatocellular Carcinoma (HCC) treated with Drug-eluting microspheres transarterial chemoembolisation (DEM-TACE) LifePearl<sup>® </sup>microspheres</p>
Terumo to Launch the Ultimaster Tansei Drug Eluting Stent in Europehttps://www.terumo-europe.com/en-emea/news/terumo-to-launch-the-ultimaster-tansei-drug-eluting-stent-in-europeTerumo to Launch the Ultimaster Tansei Drug Eluting Stent in EuropeTokyo, Japan23/05/2018 22:00:00